| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
1From the Department of Pathology, the 2Cancer Center, and the 4Department of Mathematics, Statistics, and Computer Science, University of Illinois at Chicago, Chicago, Illinois; and the 3Immunology Laboratory for Tumor Diagnosis and the 5Department of Ophthalmology, Hadassah-Hebrew University Medical Center, Jerusalem, Israel.
PURPOSE. This was a pilot study conducted to examine the expression of osteopontin in uveal melanoma and to determine whether serum osteopontin can be used in detecting metastatic uveal melanoma.
METHODS. Osteopontin mRNA was measured in three uveal melanoma cell lines of various invasive potential by real-time PCR. Tissue sections of primary and metastatic uveal melanomas were stained for osteopontin. Serum osteopontin levels were measured by ELISA assays in 15 patients with metastatic uveal melanoma and in 37 patients who were disease-free for at least 10 years after treatment of the primary tumor. Paired serum samples drawn from eight patients before and after development of metastasis were analyzed.
RESULTS. By real-time PCR, highly invasive primary and metastatic uveal melanoma cells expressed 6- and 250-fold excess osteopontin mRNA, respectively, compared with poorly invasive primary uveal melanoma cells. Tissue sections of primary uveal melanomas lacking looping vasculogenic mimicry patterns either did not stain for osteopontin or exhibited weak, diffuse staining. In primary melanomas containing looping vasculogenic mimicry patterns, strong osteopontin staining was detected in the tumor periphery where patterns were located. Diffuse strong expression of osteopontin was detected in eight samples of uveal melanomas metastatic to the liver. Serum osteopontin levels were significantly higher in patients with metastatic uveal melanoma than in patients who had been disease free for at least 10 years after treatment (P = 0.0001) or in age-matched control subjects. Serum osteopontin levels were significantly higher (P = 0.008) after metastasis than before the detection of metastasis in eight patients. When a cutoff of 10 ng/mL was used, the sensitivity and specificity of serum osteopontin in detecting metastatic melanoma was 87.5%, and the area under the receiver operator characteristic curve was 96%.
CONCLUSIONS. Osteopontin is expressed diffusely in tissue sections of hepatic metastases from uveal melanoma, and increased serum osteopontin levels correlate with melanoma metastasis to the liver with high specificity and sensitivity.
This article has been cited by other articles:
|
|
 |
|
  P.-L. Chang, L. Harkins, Y.-H. Hsieh, P. Hicks, K. Sappayatosok, S. Yodsanga, S. Swasdison, A. F. Chambers, C. A. Elmets, and K.-J. Ho Osteopontin Expression in Normal Skin and Non-melanoma Skin Tumors J. Histochem. Cytochem., January 1, 2008; 56(1): 57 - 66. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Meir, R. Dror, X. Yu, J. Qian, I. Simon, J. Pe'er, and I. Chowers Molecular Characteristics of Liver Metastases from Uveal Melanoma Invest. Ophthalmol. Vis. Sci., November 1, 2007; 48(11): 4890 - 4896. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Barak, S. Frenkel, K. Valyi-Nagy, L. Leach, M. A. Apushkin, A. Y. Lin, I. Kalickman, N. A. Baumann, J. Pe'er, A. J. Maniotis, et al. Using the Direct-Injection Model of Early Uveal Melanoma Hepatic Metastasis to Identify TPS as a Potentially Useful Serum Biomarker Invest. Ophthalmol. Vis. Sci., October 1, 2007; 48(10): 4399 - 4402. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. W. Harbour Molecular Prognostic Testing in Uveal Melanoma: Has It Finally Come of Age? Arch Ophthalmol, August 1, 2007; 125(8): 1122 - 1123. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
